Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
What’s new for psoriasis management in 2020? Treatment updates and COVID-19 concerns
+Practice
DERMATOLOGY
What’s new for psoriasis management in 2020? Treatment updates and COVID-19 concerns
Wednesday 3 June 2020, 02:03 PM

Chronic plaque psoriasis on the elbow, a commonly affected site
A comprehensive review of the pathogenesis, diagnostic characteristics and available treatments for psoriasis was outlined in a previous How to Treat (New Zealand Doctor, 13 February 2019). This article expands on changes in therapies since then
Key points, A new foam spray formulation of calcipotriol/betamethasone is now available in New Zealand for psoriasis management.
Biologics have proven superior , Pract Green w Pale Yellow
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
- Reiche L. How to treat psoriasis. New Zealand Doctor. 13 February 2019.
- Paul C, Bang B, Lebwohl M. Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile. Expert Opin Pharmacother 2017;18(1):115–21.
- LEO Pharma Ltd. New Zealand Data Sheet: Enstilar. April 2020. www.medsafe.govt.nz
- Gerdes S, Krakor M, Anger T, et al. Prospective, observational, non-interventional, multicentre study on the efficacy and tolerability of a new calcipotriol/betamethasone aerosol foam (Enstilar®) in patients with plaque psoriasis under daily practice conditions. Dermatology 2017;233(6):425–34.
- Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2020;1(1):CD011535.
- Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: A literature review. Int J Mol Sci 2020;21(5):1690.
- Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol 2018;45(3):279–86.
- Rademaker M, Baker C, Foley P, et al. Advice regarding COVID-19 and use of immunomodulators, in patients with severe dermatological diseases. Australas J Dermatol 2020;61(2):158–59.